Tavapadon may delay levodopa use in early Parkinson’s and help stabilize dosing in the later stages of the disease, with most ...

For the roughly one million Americans living with Parkinson’s disease, levodopa is the closest thing to an indispensable drug ...

Tavapadon treatment was associated with a reduced need for levodopa initiation or dose escalation in approximately 90% of ...

Treatment with Crexont statistically significantly improved “On” time without troublesome dyskinesia compared with carbidopa/levodopa IR. The Food and Drug Administration (FDA) has approved Crexont ® ...

Northwestern University scientists have identified a specific brain circuit mechanism that may explain why long-term levodopa use in Parkinson’s patients can trigger involuntary movements. Their mouse ...

Neuromodulation is an adjunct to medication for Parkinson’s symptom management, with growing interest in whether it could one ...

Very long acting (> 6–8 h) levodopa preparations are still likely to represent the next chapter in the medical treatment of PD. Continuous-infusion levodopa gel, long-acting levodopa pills, ...

Amneal to hold CREXONT launch symposium and scientific presentations at the International Congress of Parkinson’s Disease and Movement Disorders on Sept. 27 – Oct. 1, 2024 BRIDGEWATER, N.J.--(BUSINESS ...

The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday. The treatment is a ...